Case reports in oncology · 2025
Efficacy and Blood Concentrations of Cetuximab in a Hemodialysis Patient with Tongue Squamous Cell Carcinoma: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Niu Ting-Ting, Zhang Wei-Yang, Han Ling, Shi Hui-Jie, Piao Ying, Ren Li-Wei, Wu Shi-Hai
Аннотация
INTRODUCTION: Cetuximab is an effective therapy for unresectable locoregionally advanced head and neck cancer, but for patients with end-stage renal disease (ESRD), clinical trials seldom provide evidence for the efficacy and safety of cetuximab.
CASE PRESENTATION: We report this case of 46-year-old male patient with stage IVa tongue squamous cell carcinoma who is on maintenance hemodialysis for diabetic nephropathy. He tolerated the therapy well and had a stable disease of the carcinoma. We determined cetuximab concentration and showed that pharmacokinetics of cetuximab in this ESRD patient was similar to healthy subjects.
CONCLUSION: Cetuximab can be used safely and effectively in head and neck cancer patients with ESRD, and we have provided an example of pharmacokinetics of cetuximab in renal failure patient.
CASE PRESENTATION: We report this case of 46-year-old male patient with stage IVa tongue squamous cell carcinoma who is on maintenance hemodialysis for diabetic nephropathy. He tolerated the therapy well and had a stable disease of the carcinoma. We determined cetuximab concentration and showed that pharmacokinetics of cetuximab in this ESRD patient was similar to healthy subjects.
CONCLUSION: Cetuximab can be used safely and effectively in head and neck cancer patients with ESRD, and we have provided an example of pharmacokinetics of cetuximab in renal failure patient.